CTCL Clinical Trial
Official title:
Post-marketing Surveillance of StrataCTX® Flexible Wound Dressing for Use as a Steroid Sparing Agent
The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.
Topical steroids are the mainstays of treatment for many cutaneous reactions and disorders. Steroids are known to cause many side effects and few effective pharmacologic alternatives exist. Contact dermatitis is observed in 56% of patients with cutaneous T-cell lymphoma (CTCL) being treated with topical mechlorethamine gel. This usually requires chronic treatment with mid-to high-potency steroids. Numerous chemo/immunotherapies are associated with cutaneous reactions including paronychia, hand and foot syndrome, and acneiform rash. Skin toxicity often requires dose reduction of cancer therapies and a variety of skin directed therapies including topical antibiotics and topical steroids. Cutaneous reactions are often the earliest manifestation of acute graft versus host disease. Skin manifestations can be debilitating and treatment usually requires high potency topical steroids. Additional therapies are needed for the treatment of disorders that rely on topical steroids. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02556463 -
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT02757248 -
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL
|
Phase 1 | |
| Recruiting |
NCT05879458 -
Ritlecitinib in CTCL
|
Phase 2 | |
| Completed |
NCT04171791 -
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)
|
Phase 1 | |
| Recruiting |
NCT03240211 -
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
|
Phase 1 | |
| Completed |
NCT03239392 -
A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL
|
Phase 1/Phase 2 |